source
- FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerationsThe U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
- Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trialInhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…BioPharma Dive · 4mo agoPositive readoutPositive